肝硬化患者门静脉血栓形成的危险因素
The risk factors of portal vein thrombosis in patients with liver cirrhosis.
作者信息
Cagin Yasir Furkan, Bilgic Yilmaz, Berber İlhami, Yildirim Oguzhan, Erdogan Mehmet Ali, Firat Feyza, Arslan Ahmet Kadir, Colak Cemil, Seckin Yuksel, Harputluoglu Murat
机构信息
Department of Gastroenterology, Medical Faculty, Inonu University, 44280 Malatya, Turkey.
Clinic of Hematology, Malatya Training and Education Hospital, 44330 Malatya, Turkey.
出版信息
Exp Ther Med. 2019 Apr;17(4):3189-3194. doi: 10.3892/etm.2019.7300. Epub 2019 Feb 22.
This study was designed to identify and assess risk factors for portal vein thrombosis (PVT) in patients with cirrhosis. A total of 98 cirrhosis patients with PVT were identified and 101 cirrhosis patients without PVT were chosen as the control group in this retrospective study. Several variables were measured and the two groups PVT and non-PVT were compared statistically. PVT was identified in 98 patients (10%). Significant differences in hematocrit, international normalized ratio, albumin, bilirubin and glucose were determined between the groups (P<0.05). Out of the thrombophilic risk factors in the patients with PVT factor V Leiden was identified in 8.8%, prothrombin gene 6.6% and methylenetetrahydrofolate reductase 2.2%. There was no difference in survival time between groups (P>0.05).
本研究旨在识别和评估肝硬化患者门静脉血栓形成（PVT）的危险因素。在这项回顾性研究中，共确定了98例患有PVT的肝硬化患者，并选择了101例无PVT的肝硬化患者作为对照组。测量了几个变量，并对PVT组和非PVT组进行了统计学比较。98例患者（10%）被确诊为PVT。两组之间在血细胞比容、国际标准化比值、白蛋白、胆红素和葡萄糖方面存在显著差异（P<0.05）。在PVT患者的血栓形成危险因素中，8.8%的患者检测到凝血因子V莱顿突变，6.6%检测到凝血酶原基因，2.2%检测到亚甲基四氢叶酸还原酶。两组之间的生存时间没有差异（P>0.05）。
Zotero 插件